science1 distinct publisher
Phase III for a bespoke mRNA cancer therapy repriced the sequencing vendors, not just Moderna
Merck and Moderna put out no efficacy figures. Illumina still rose 16% and PacBio 18%, because an approved per-patient therapy implies a sequencing run per patient.
Publishers:genengnews.com
Reality
- Evidence30
- Adoption22
- Hype gap+45
- Incentives68
- Confidence44